A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Astellas Pharma Inc
InnoPharmax Inc.
Novartis
Travera Inc
Virogin Biotech Ltd.
J-Pharma Co., Ltd.
Tango Therapeutics, Inc.
Taiho Oncology, Inc.
Hutchmed
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Rigel Pharmaceuticals